These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 26254539)

  • 1. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas.
    Li Y; Fu SY; Wang LH; Wang FY; Wang NN; Cao Q; Wang YT; Yang JY; Wu CF
    Cancer Lett; 2015 Dec; 369(1):86-96. PubMed ID: 26254539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
    Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
    Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
    Wang NN; Wang LH; Li Y; Fu SY; Xue X; Jia LN; Yuan XZ; Wang YT; Tang X; Yang JY; Wu CF
    Exp Cell Res; 2018 Jan; 362(1):72-82. PubMed ID: 29155365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
    Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
    PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
    Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
    J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
    Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
    Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
    Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
    Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
    Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
    Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.